RxDoctor Payments Data

Melanie Gramling, APRN

Adult Health · Fort Smith, ARNPI 1194024158

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Novartis at 30.8% of the total.

$1,163in general payments, 2019–2025

Across 70 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$358
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$172
  • AstraZeneca$127
  • Medtronic$80
  • Philips North America LLC$60
  • Merck$50
  • plus $316 from 11 others

What the payments were for

  • Food & beverage$1,163100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,163 in reported general payments places this provider in the 65th percentile of 154 adult health providers in Arkansas.

See all adult health providers in Arkansas

Medicare billing

Part B allowed, 2024
$75,877
Medicare patients
444
Services billed
1,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban331$297,075
EntrestoSacubitril/Valsartan145$147,716
Repatha SureclickEvolocumab100$72,511
XareltoRivaroxaban60$63,311
FarxigaDapagliflozin Propanediol38$34,261
JardianceEmpagliflozin27$30,467
BrilintaTicagrelor40$24,151
Metoprolol Succinate653$8,797
Repatha SyringeEvolocumab15$6,081
Ranolazine ErRanolazine61$5,119
Atorvastatin Calcium678$5,115
Flecainide Acetate59$4,079
ClopidogrelClopidogrel Bisulfate487$3,581
Prasugrel Hcl30$2,870
Ezetimibe84$2,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$297,075331 claims
NovartisEntresto$358$147,716145 claims
Johnson & JohnsonXarelto$46$63,31160 claims
AstraZenecaFarxiga, Brilinta$127$58,41278 claims
Boehringer IngelheimJardiance$48$30,46727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 154 adult health providers in Arkansas.

Other adult health in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →